Fish Analysis, Multiple Myeloma Profile

Cytogenetics Test Requisition Specimen Information Billing Information Contact Us CPT Codes     Print Page


Pseudonyms: Multiple Myeloma Panel, MM Panel

TURNAROUND TIME: 7 to 10 days
TESTING METHODOLOGY: Fluorescence in situ hybridization
  • Collect: 2 mL bone marrow aspirate in sodium heparin (green)
  • Minimum Collection: 1 mL bone marrow
  • Transport: bone marrow in sodium heparin (green) at 20-25°C; specimen should arrive in the laboratory within 24 hours of collection
  • Stability: Ambient: 24 hours; Refrigerated: 24 hours; Frozen: unacceptable
  • Unacceptable Conditions: Frozen or clotted specimens; paraffin-embedded specimens; specimens in anticoagulants other than sodium heparin.
A Cytogenetics Laboratory Test Requisition must accompany the specimen. Contact the Cytogenetics Laboratory at 918-502-1722 to obtain further information.
Test Summary: Probes included: ATM, D13S319, IGH, TP53
A dual-color FISH analysis performed on interphase cells using a probe for the ATM gene on chromosome 11q22.3 and a probe for the p53 gene on chromosome 17p13.1; analysis of 200 interphase cells.
A single-color FISH analysis performed on interphase cells using a probe for the D13S319 locus on chromosome 13q14; analysis of 200 interphase cells.
A dual-color, break-apart FISH analysis performed on interphase cells using probes for 5' and 3' ends of the IGH gene on chromosome 14q32; analysis of 200 interphase cells
Interpretation: A positive result is reported when the percent of cells with an abnormality exceeds the normal reference range for any of the probes. The detection of an abnormal clone indicates a diagnosis of multiple myeloma with the specific chromosome abnormality. A negative result indicates no abnormality was observed but does not rule out the presence of a neoplastic disorder.
FDA Approval: This test is not approved by the FDA and it should used as an adjunct to other clinical and pathological information.
Indications for Use:
  • Aid in the diagnosis of multiple myeloma
  • Identify patients with multiple myeloma with deletions of the ATM gene, the D13S319 locus and/or the p53 gene and/or rearrangement of the IGH gene
  • Provide prognostic indicators for patients with multiple myeloma